INTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
INTS is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who does not want to wait for a better entry. The stock has some positive pre-market momentum and a constructive MACD, but the overall trend is still weak, fundamentals remain deeply unprofitable, and there is no strong catalyst today. Best view: hold off until either the trend improves or a clearer catalyst appears.
INTS is trading pre-market at 5.35, up 2.69%, which is a short-term positive sign. MACD histogram is above zero and expanding, showing improving momentum. However, RSI_6 at 41.12 is still neutral and does not confirm strong buying pressure. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the broader trend remains down. Price is near pivot resistance at 5.209 and just below R1 at 5.377, so the stock is testing an area where upside may stall. The technical picture is mixed: short-term momentum is improving, but the long-term trend is still weak.
["Pre-market price is up 2.69%, showing early positive momentum.", "MACD histogram is positive and expanding, suggesting improving short-term trend strength.", "Freedom Broker upgraded the stock to Buy and cited financing enabling the restart of INVINCIBLE-4 enrollment.", "Alliance Global raised its price target sharply to $30 and maintained a Buy rating."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "Bearish moving averages still show the broader trend is weak.", "Hedge fund and insider activity are neutral, with no notable accumulation signals.", "No recent congress trading data is available.", "The company remains unprofitable with negative net income and EPS in the latest quarter."]
In 2025/Q4, revenue was still 0, so there is no meaningful top-line growth yet. Net income was -3,051,000, and EPS was -1.31, both negative and weaker year over year. Gross margin remained 0. This latest quarter shows the company is still in a pre-revenue or very early commercialization stage, with no evidence of strong operating growth yet.
Analyst sentiment has improved recently. On 2026-03-30, Freedom Broker upgraded Intensity Therapeutics to Buy from Hold and lowered the price target to $20 from $37.50, citing financing support for restarting enrollment in INVINCIBLE-4. On 2026-03-13, Alliance Global raised its target to $30 from $3.50 and kept a Buy rating after the reverse split. Wall Street’s bullish case is based on pipeline value and restarted trial activity. The bearish side is that targets were still cut or adjusted after delays, reflecting execution risk and a long timeline before value realization.
